# Michael F. Berger

Source: https://onco.cc/people/michael-berger/  
OnCo record `michael-berger` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Built MSK-IMPACT, the tumour sequencing test used on more than 100,000 patients and the first FDA-authorised hospital panel.

## Summary

Michael Berger led the development of MSK-IMPACT, the hybrid-capture sequencing assay that profiles hundreds of cancer genes in every MSKCC patient and became the first laboratory-developed tumour panel authorised by the FDA. The 2017 Nature Medicine paper on 10,000 profiled patients showed how prospective clinical sequencing enables trial matching. He also co-developed MSK-ACCESS for ctDNA and OncoKB with Debyani Chakravarty.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: genomics; precision-oncology; diagnostics
- Role: Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
- Specialisms: Clinical cancer genomics; Tumour sequencing assays; Computational biology; Precision oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT

## Connected records

- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/)
- drugs: [FoundationOne CDx / Liquid CDx](https://onco.cc/drugs/foundationone-cdx/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- key papers: [TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features](https://onco.cc/key-papers/paper-tcga-pancancer-atlas-cell-2018/)

---
JSON: https://onco.cc/api/v1/entities/michael-berger.json